VISCHER advised Memo Therapeutics on the financing.Memo Therapeutics AG, a late-stage biotech company developing best-in-class therapeutic antibodies closed a CHF25 million series C financing round led…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
